OncoMatch/Clinical Trials/NCT06151106
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Is NCT06151106 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Chidamide combined with Duvillisib for peripheral t cell lymphoma.
Treatment: Chidamide combined with Duvillisib — To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anthracycline-containing chemotherapy — first-line
Relapsed and refractory patients who have received at least first-line systemic treatment with anthracycline-containing drugs in the past
Cannot have received: PI3K inhibitor
Exception: disease has progressed during the treatment period (within 6 months after the last use)
Any PI3K inhibitor has been used before and the disease has progressed during the treatment period (within 6 months after the last use)
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5×10^9/L, platelet ≥ 75×10^9/L, Hb ≥ 80g/L
Liver function
total bilirubin (TBiL) ≤ 1.5 ULN, AST/ALT ≤ 2.5 ULN (≤ 5 ULN if liver infiltrated by lymphoma cells)
Cardiac function
No clinically significant abnormal rhythm or conduction, hereditary QT interval syndrome, QTcF ≤ 480 msec, no drugs that may cause QT interval delay or torsade de pointes, no NYHA grade 3 or above, LVEF ≥ 40%, no uncontrolled hypertension (SBP ≤ 160 mmHg, DBP ≤ 100 mmHg), no acute MI, unstable angina, or CABG within 6 months
Routine blood examination: absolute neutrophil count ≥ 1.5× 10 9/L, platelet ≥ 75x10 9/L, Hb ≥ 80g/L. total bilirubin (TBiL) > 1.5 ULN, or AST or ALT >2.5ULN, except the following situations. if patients with liver infiltrated by lymphoma cells, AST and ALT < 5ULN could be enrolled. all kinds of clinically significant abnormal rhythm or conduction need clinical pre-diagnosis Hereditary QT interval syndrome or QTcF>480 msec or taking drugs that may cause Qt interval delay or torsade de pointes. A variety of clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, and coronary artery bypass grafting in the first 6 months of the group, with New York's cardiology (NYHA) classification of grade 3 or above. Left ventricular ejection fraction (LVEF )<40%, or uncontrolled blood pressure controlled by drugs (Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mgHg).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify